Citation Impact
Citing Papers
Profound Coordinated Alterations of Intratumoral NK Cell Phenotype and Function in Lung Carcinoma
2011
TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells
2017 Standout
Intracellular Tumor-Associated Antigens Represent Effective Targets for Passive Immunotherapy
2012 StandoutNobel
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
2010 Standout
Genetic Evolution of T-cell Resistance in the Course of Melanoma Progression
2014
Two Distinct Mechanisms of Augmented Antitumor Activity by Modulation of Immunostimulatory/Inhibitory Signals
2010 StandoutNobel
Cancer Immunotherapy Targeting the High Molecular Weight Melanoma-Associated Antigen Protein Results in a Broad Antitumor Response and Reduction of Pericytes in the Tumor Vasculature
2008
The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research
2009 StandoutNobel
Immunotherapy of cancer in 2012
2012
HER‐2/neu antigen loss and relapse of mammary carcinoma are actively induced by T cell‐mediated anti‐tumor immune responses
2007
MHC Class I Antigens and Immune Surveillance in Transformed Cells
2007
Cancer Invasion and the Microenvironment: Plasticity and Reciprocity
2011 Standout
Elements of cancer immunity and the cancer–immune set point
2017 StandoutNature
HNPCC versus sporadic microsatellite-unstable colon cancers follow different routes toward loss of HLA class I expression
2007
Oncology Meets Immunology: The Cancer-Immunity Cycle
2013 Standout
MHC class I molecules act as tumor suppressor genes regulating the cell cycle gene expression, invasion and intrinsic tumorigenicity of melanoma cells
2012
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
2019 Standout
Natural killer cell–directed therapies: moving from unexpected results to successful strategies
2008
Deciphering and Reversing Tumor Immune Suppression
2013
Imaging in the era of molecular oncology
2008 StandoutNature
Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future
2017 Standout
Mesenchymal stem cells in health and disease
2008 Standout
New insights into the mechanisms of epithelial–mesenchymal transition and implications for cancer
2018 Standout
Tumor-Associated Macrophages: From Mechanisms to Therapy
2014 Standout
Personalized cancer vaccines: Targeting the cancer mutanome
2016
Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity
2015 Standout
Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity
2017 StandoutNobel
Immune surveillance of tumors
2007
Intratumoral expression levels of PD-L1, GZMA, and HLA-A along with oligoclonal T cell expansion associate with response to nivolumab in metastatic melanoma
2016
Method for generation of in vivo biotinylated recombinant antibodies by yeast mating
2006
Epidemiology of Brain Tumors
2007
Immunity, Inflammation, and Cancer
2010 Standout
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
2016 Standout
Malignant Gliomas in Adults
2008 Standout
Tumor cell expression of HLA-DM associates with a Th1 profile and predicts improved survival in breast carcinoma patients
2006
The clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans
2021 StandoutNobel
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
2017 Standout
T Cell Surveillance of Oncogene-Induced Prostate Cancer Is Impeded by T Cell-Derived TGF-β1 Cytokine
2011 StandoutNobel
The tumor microenvironment and its role in promoting tumor growth
2008 Standout
Cancer immunotherapy comes of age
2011 StandoutNature
The immune contexture in human tumours: impact on clinical outcome
2012 Standout
WHO grade associated downregulation of MHC class I antigen-processing machinery components in human astrocytomas: does it reflect a potential immune escape mechanism?
2007
Targeting autophagy in cancer
2017 Standout
Regulatory T cells in tumor immunity
2010 StandoutNobel
Immunotherapy of Diffuse Gliomas: Biological Background, Current Status and Future Developments
2009 Standout
Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer
2013 Standout
Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting
2012 StandoutNatureNobel
The Pathobiology of Vascular Dementia
2013 Standout
Favorable outcome in clinically stage II melanoma patients is associated with the presence of activated tumor infiltrating T‐lymphocytes and preserved MHC class I antigen expression
2008
Potentiation of immunomodulatory antibody therapy with oncolytic viruses for treatment of cancer
2014
Microenvironmental regulation of tumor progression and metastasis
2013 Standout
VEGF in Signaling and Disease: Beyond Discovery and Development
2019 Standout
The prognostic landscape of genes and infiltrating immune cells across human cancers
2015 Standout
Cellular and Functional Characterization of Immunoresistant Human Glioma Cell Clones Selected With Alloreactive Cytotoxic T Lymphocytes Reveals Their Up-regulated Synthesis of Biologically Active TGF-β
2007
A guide to cancer immunotherapy: from T cell basic science to clinical practice
2020 Standout
Immunogenic cell death and DAMPs in cancer therapy
2012 Standout
Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response
2018 Standout
The Human Cancer Antigen Mesothelin Is More Efficiently Presented to the Mouse Immune System when Targeted to the DEC‐205/CD205 Receptor on Dendritic Cells
2009 StandoutNobel
Granzyme B degradation by autophagy decreases tumor cell susceptibility to natural killer-mediated lysis under hypoxia
2013
Intensified and protective CD4+ T cell immunity in mice with anti–dendritic cell HIV gag fusion antibody vaccine
2006 StandoutNobel
Transmembrane Signaling Proteoglycans
2010
Integrated NY-ESO-1 antibody and CD8+T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab
2011 StandoutNobel
Immunological response induced by abagovomab as a maintenance therapy in patients with epithelial ovarian cancer: relationship with survival—a substudy of the MIMOSA trial
2014
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
2011 StandoutScience
Human Neuroblastoma Cells Trigger an Immunosuppressive Program in Monocytes by Stimulating Soluble HLA-G Release
2007
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients
2008 StandoutNobel
Immune cells in colorectal cancer: prognostic relevance and therapeutic strategies
2008
Cancer Genome Landscapes
2013 StandoutScience
Reactive Oxygen Species (ROS)-Based Nanomedicine
2019 Standout
HUMAN T CELL RESPONSES AGAINST MELANOMA
2005
Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+regulatory T cells, evoking antitumor immune responses in humans
2013 StandoutNobel
Surface Plasmon Resonance Sensors for Detection of Chemical and Biological Species
2008 Standout
Neoantigens in cancer immunotherapy
2015 StandoutScience
Chemodynamic Therapy: Tumour Microenvironment‐Mediated Fenton and Fenton‐like Reactions
2018 Standout
Immunogenicity of Human Mesenchymal Stem Cells in HLA-Class I-Restricted T-Cell Responses Against Viral or Tumor-Associated Antigens
2008
Cancer immunotherapy using checkpoint blockade
2018 StandoutScience
Immunoselective Pressure and Human Leukocyte Antigen Class I Antigen Machinery Defects in Microsatellite Unstable Colorectal Cancers
2005
Innate or Adaptive Immunity? The Example of Natural Killer Cells
2011 StandoutScience
Mechanisms of malignant glioma immune resistance and sources of immunosuppression.
2006
Works of Michael Campoli being referenced
Functional and Clinical Relevance of Chondroitin Sulfate Proteoglycan 4
2010
A method to generate antigen-specific mAb capable of staining formalin-fixed, paraffin-embedded tissue sections
2005
Tumor escape mechanisms: potential role of soluble HLA antigens and NK cells activating ligands
2008
Enhancement of scFv fragment reactivity with target antigens in binding assays following mixing with anti-tag monoclonal antibodies
2004
Human High Molecular Weight-Melanoma-Associated Antigen (HMW-MAA): A Melanoma Cell Surface Chondroitin Sulfate Proteoglycan (MSCP) with Biological and Clinical Significance
2004
Immunotherapy of Melanoma Targeting Human High Molecular Weight Melanoma‐Associated Antigen: Potential Role of Nonimmunological Mechanisms
2004
Classical and Nonclassical HLA Class I Antigen and NK Cell–Activating Ligand Changes in Malignant Cells: Current Challenges and Future Directions
2005
Mechanisms of Tumor Evasion
2007
Selective monomorphic and polymorphic HLA class I antigenic determinant loss in surgically removed melanoma lesions
2005
CSPG4 in Cancer: Multiple Roles
2010
HLA antigen and NK cell activating ligand expression in malignant cells: a story of loss or acquisition
2011
HLA class I defects in malignant lesions: What have we learned?
2003
HLA class I antigen loss, tumor immune escape and immune selection
2002
Human Leukocyte Antigen and Antigen Processing Machinery Component Defects in Astrocytic Tumors
2005
HLA Antigen Changes in Malignant Tumors of Mammary Epithelial Origin: Molecular Mechanisms and Clinical Implications
2004
Immune Selection of Hot-Spot β2-Microglobulin Gene Mutations, HLA-A2 Allospecificity Loss, and Antigen-Processing Machinery Component Down-Regulation in Melanoma Cells Derived from Recurrent Metastases following Immunotherapy
2005
Immunotherapy of Malignant Disease with Tumor Antigen–Specific Monoclonal Antibodies
2009
A fresh look at an old story: revisiting HLA class II antigen expression by melanoma cells
2006